We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+4.88%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$197M
AUM Growth
-$21.3M
(-9.8%)
Cap. Flow
-$17.6M
Cap. Flow
% of AUM
-8.93%
Top 10 Holdings %
Top 10 Hldgs %
62.37%
Holding
44
New
8
Increased
13
Reduced
17
Closed
5
Top Buys
| 1 |
Kura Oncology
KURA
|
+$11.5M |
| 2 |
Q32 Bio
QTTB
|
+$8.06M |
| 3 |
uniQure
QURE
|
+$7.65M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$5.94M |
| 5 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$5.92M |
Top Sells
| 1 |
Cigna
CI
|
+$16.7M |
| 2 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$9.43M |
| 3 |
HNGR
Hanger Inc.
HNGR
|
+$8.55M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$7.79M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$7.33M |
Sector Composition
| 1 | Healthcare | 98.13% |
| 2 | Technology | 0.92% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Evolus
EOLS
$392M
| $1.65M | 0.84% |
+112,590
| New | +$2.23M |
|
27
Personalis
PSNL
$1.65B
| $1.53M | 0.78% |
+56,446
| New | +$1.6M |
|
|
SRRA
28
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.5M | 0.76% |
67,040
+5,598
| +9% | +$271K |
|
|
UROV
29
DELISTED
Urovant Sciences Ltd.
UROV
| $1.13M | 0.57% |
142,620
+42,750
| +43% | +$351K |
|
|
ARQL
30
DELISTED
Arqule Inc
ARQL
| $921K | 0.47% |
+83,675
| New | +$582K |
|
31
Tempest Therapeutics
TPST
$17.1M
| $854K | 0.43% |
379
-1,010
| -73% | -$2.97M |
|
|
MODV
32
DELISTED
ModivCare
MODV
| $842K | 0.43% |
14,677
-37,647
| -72% | -$2.44M |
|
33
ADMA Biologics
ADMA
$2.01B
| $719K | 0.37% |
+185,721
| New | +$820K |
|
|
NVRO
34
DELISTED
NEVRO CORP.
NVRO
| $713K | 0.36% |
11,000
-117,765
| -91% | -$7.33M |
|
35
United Therapeutics
UTHR
$22.6B
| $671K | 0.34% |
+8,600
| New | +$804K |
|
|
CDTX
36
DELISTED
Cidara Therapeutics
CDTX
| $603K | 0.31% |
17,948
+6,935
| +63% | +$288K |
|
|
KZR
37
DELISTED
Kezar Life Sciences
KZR
| $264K | 0.13% |
+3,422
| New | +$532K |
|
38
Neurogene
NGNE
$787M
| $9K | ﹤0.01% |
182
-1,233
| -87% | -$63.4K |
|
39
Avalo Therapeutics
AVTX
$975M
| – | – |
-40
| Closed | -$665K |
|
40
Enanta Pharmaceuticals
ENTA
$385M
| – | – |
-709
| Closed | -$68K |
|
|
EXAS
41
DELISTED
Exact Sciences
EXAS
| – | – |
0
| – | – |
|
42
MacroGenics
MGNX
$275M
| – | – |
-107,560
| Closed | -$1.93M |
|
43
MeiraGTx Holdings
MGTX
$1.16B
| – | – |
-91,317
| Closed | -$1.57M |
|
|
WAGE
44
DELISTED
WageWorks, Inc.
WAGE
| – | – |
-115,926
| Closed | -$4.38M |
|
Similar funds
PL
BFC
ACM
FFWA
SAM
CBB
AIG
IA